Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer

Video

In Partnership With:

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Leslie M. Randall, MD, MAS, ​professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet need​s in platinum-resistant ovarian cancer.

 Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.

 Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.

As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology